rs867288458
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM2PM5PP2PP3
The ENST00000372435.10(PRPS1):c.641G>A(p.Arg214Gln) variant causes a missense change. The variant allele was found at a frequency of 0.00000182 in 1,098,234 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 1 hemizygotes in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R214P) has been classified as Likely pathogenic.
Frequency
Consequence
ENST00000372435.10 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PRPS1 | NM_002764.4 | c.641G>A | p.Arg214Gln | missense_variant | 5/7 | ENST00000372435.10 | NP_002755.1 | |
PRPS1 | NM_001204402.2 | c.29G>A | p.Arg10Gln | missense_variant | 2/4 | NP_001191331.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PRPS1 | ENST00000372435.10 | c.641G>A | p.Arg214Gln | missense_variant | 5/7 | 1 | NM_002764.4 | ENSP00000361512 | P1 |
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD4 exome AF: 0.00000182 AC: 2AN: 1098234Hom.: 0 Cov.: 31 AF XY: 0.00000275 AC XY: 1AN XY: 363588
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Dec 02, 2019 | - - |
Charcot-Marie-Tooth Neuropathy X Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 20, 2023 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 214 of the PRPS1 protein (p.Arg214Gln). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with PRPS1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1320158). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PRPS1 protein function with a negative predictive value of 80%. This variant disrupts the p.Arg214 amino acid residue in PRPS1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 28967191; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Arts syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | 3billion | Jun 21, 2023 | It is not observed in the gnomAD v2.1.1 dataset (PM2). A different missense change at the same codon (p.Arg214Trp) has been reported as pathogenic/likely pathogenic (ClinVar ID: VCV000446163.5 PM5). Missense changes are a common disease-causing mechanism (PP2). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.696, 3Cnet: 0.610, PP3). However the evidence of pathogenicity is insufficient at this time. Therefore, this variant is classified as a variant of uncertain significance according to the recommendation of ACMG/AMP guideline. - |
Retinal dystrophy Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Institute of Human Genetics, Univ. Regensburg, Univ. Regensburg | Jan 01, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at